|
1 Indications And Usage Inlyta Is A Kinase Inhibitor Indicated: In Combination With Avelumab, For The First-Line Treatment Of Patients With Advanced Renal Cell Carcinoma (Rcc). ( 1.1 ) In Combination With Pembrolizumab, For The First-Line Treatment Of Patients With Advanced Rcc. ( 1.1 ) As A Single Agent, For The Treatment Of Advanced Renal Cell Carcinoma (Rcc) After Failure Of One Prior Systemic Therapy. ( 1.2 ) 1.1 First-Line Advanced Renal Cell Carcinoma Inlyta In Combination With Avelumab Is Indicated For The First-Line Treatment Of Patients With Advanced Renal Cell Carcinoma (Rcc). Inlyta In Combination With Pembrolizumab Is Indicated For The First-Line Treatment Of Patients With Advanced Renal Cell Carcinoma. 1.2 Second-Line Advanced Renal Cell Carcinoma Inlyta As A Single Agent Is Indicated For The Treatment Of Advanced Renal Cell Carcinoma (Rcc) After Failure Of One Prior Systemic Therapy.
|